DeepMirror, a College of Cambridge spin-out firm creating intuitive design software program for the invention of novel therapeutic medication, right now introduced the launch of its Early Entry Programme after a profitable closed beta programme throughout which chemists have been invited to check the software program over a number of months. The software program permits customers to faucet into AI-driven insights to enhance and speed up molecular design throughout the drug discovery pipeline by a safe and user-friendly interface which makes AI-powered drug discovery so simple as utilizing a spreadsheet.
AI-enabled drug discovery programmes usually begin with pharmaceutical firms partnering with AI firms to ship insights for his or her drug discovery efforts. Nevertheless, this strategy requires intensive crosstalk between the 2 events, leading to lengthy ready instances and huge quantities of assets spent on each side. DeepMirror goals to unravel this subject by enabling R&D groups to hold out AI-driven analysis from day one, with seamless workflow integration and with out the necessity to have interaction exterior stakeholders, develop inside groups or software program, or relinquish any mental property. To affix the waitlist for the Early Entry Programme join right here.
DeepMirror’s objective is to fast-track the drug discovery course of, for instance within the Hit-to-Lead and Lead Optimisation phases, with the flexibility to foretell related properties resembling drug binding, (bio-)exercise, and toxicity, each from consumer information and from giant proprietary curated databases. Laboratory outcomes can be utilized to refine predictions and generate novel drug candidates for additional experimentation, finally accelerating the drug discovery course of by as much as 4 instances as estimated by the Wellcome Belief and the Boston Consulting Group (1).
“Our mission is to make AI-powered drug design so simple as shopping the online. After 12 months of growth and a profitable beta testing programme, we’re excited to formally launch DeepMirror to early adopters. We’re inviting researchers to get in contact to make use of our safe and user-friendly AI platform for drug design. DeepMirror was already used on energetic drug discovery programmes and led to the invention of novel lead sequence and impressed the synthesis of novel compounds.”
Dr Max Jakobs, Co-Founder and CEO of DeepMirror
“DeepMirror is a big step ahead within the democratization of machine studying fashions and their utility in drug discovery. Its user-friendly interface allows medicinal chemists of all ranges to deploy this highly effective strategy in a fraction of the time. The flexibility to use DeepMirror’s platform to any desired endpoint, whether or not or not it’s efficiency, selectivity, and even ADME properties, empowers its customers to make extra knowledgeable choices and to take action quicker. We’re at all times on the lookout for new instruments to enhance the effectivity of our DMTA cycles and DeepMirror helps be sure that no stone is left unturned.”
Dr Andrew McTeague, Senior Scientist, Medicinal Chemistry at Morphic Therapeutic
For extra details about DeepMirror, please go to: www.deepmirror.ai/weblog.
